Keros Therapeutics (NASDAQ:KROS) Sets New 1-Year Low – Here’s What Happened

Keros Therapeutics, Inc. (NASDAQ:KROS)’s stock price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $15.67 and last traded at $15.98, with a volume of 228784 shares changing hands. The stock had previously closed at $16.42.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on KROS shares. Guggenheim lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, December 16th. Wedbush reaffirmed an “outperform” rating and issued a $84.00 price objective on shares of Keros Therapeutics in a report on Thursday, November 7th. Scotiabank lowered their target price on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a research note on Friday, December 13th. Wells Fargo & Company lifted their price target on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $75.00.

Keros Therapeutics Trading Up 1.2 %

The business has a fifty day simple moving average of $48.78 and a two-hundred day simple moving average of $50.02. The company has a market cap of $641.23 million, a PE ratio of -3.04 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million during the quarter. During the same quarter in the prior year, the company posted ($1.33) earnings per share. The company’s quarterly revenue was up 4750.0% on a year-over-year basis. Equities analysts expect that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

A number of large investors have recently made changes to their positions in the stock. KBC Group NV grew its holdings in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new position in Keros Therapeutics during the third quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Keros Therapeutics in the 2nd quarter valued at about $128,000. Finally, LMR Partners LLP purchased a new stake in shares of Keros Therapeutics in the 3rd quarter valued at approximately $213,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.